Curie-Cancer and Harmonic Pharma sign a partnership agreement for exploring the anti-cancer activity of several compounds

  • Email
  • Print

Under this multi-year research collaboration, Curie-Cancer will give Harmonic Pharma access to its extensive collection of patient-derived xenografts representative of human tumors
 
Paris and Villers les Nancy, France, November 5, 2012 - Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Harmonic Pharma, which is developing solutions for extending the therapeutic application of compounds already on the market, announce today that they have entered into a research collaboration aimed at exploring the anti-cancer activity of several molecules in Harmonic Pharma’s portfolio.
 
Harmonic Pharma’s main focus is on identifying new therapeutic uses for compounds that are already on the market or at an advanced stage of development, using an approach known as molecular repositioning. Since these compounds have already proven to be well tolerated in humans, Harmonic Pharma’s repositioning activities bring considerable gains in terms of time and resources.
 
“Harmonic Pharma’s know-how speeds up the process of making drugs available to patients. That is why partnering with the Institut Curie, expert in our therapeutic targeted fields, seemed an obvious option for our cancer project,” said Michel Souchet, Harmonic Pharma’s CEO. “For a young, innovative firm like ours, partnering with a world-leading center like the Institut Curie gives us access to experimental models, fundamental knowledge and expertise related to the development of cancer.”
 
New therapeutic activities in existing drugs are often discovered by chance or through an empirical approach. “Harmonic Pharma’s researchers have succeeded in rationalizing this process thanks to the development of original solutions for comparing molecular footprints in 3D,” said Arnaud Sinan Karaboga, scientific director of Harmonic Pharma. “We use a proprietary database containing several thousand active principles that are selected, classified and annotated as a function of their mode of action and their therapeutic applications. Our researchers have thus been able very quickly to identify several unpatented compounds acting on a cellular membrane receptor involved in certain cancers.”
 
The targeted biological receptor, already known for its role in facilitating the entry of the HIV virus into lymphocytes, is also involved in three of the most important stages of the development of cancer: tumor proliferation, the migration of tumor cells to other tissues and the invasion of these other tissues, which results in the formation of distant metastases (in the bone, the lungs, the brain and other areas).
 
Key contribution comes from extensive collection of animal models particularly representative of tumors in man

To validate the initial observations made in in vitro cellular models, Curie-Cancer gave Harmonic Pharma access to animal models that are highly representative of cancer in humans, as well as to the know-how of its researchers with a deep understanding of metastatic processes. Institut Curie’s extensive collection of mice xenografted with tumors taken from human patients on the operating table, which are therefore representative of the tumors seen in man, is proving an especially valuable tool for therapeutic development.

“By studying the results that Harmonic Pharma has already obtained in vitro, and taking account of the role of the receptor of interest in these types of cancer, we rapidly turned towards three types of model for which we have a wide variety of tumors and considerable experience, namely breast cancer, lung cancer and eye cancer,” explained Didier Decaudin, who runs the Institut Curie’s preclinical investigation laboratory.

Depending on the results, Curie-Cancer may take over some of the molecules being studied and put them through clinical trials.
 
This research agreement involves both applied research in the development of products that could be rapidly commercialized and fundamental research that will help improve understanding of the receptor’s role in breast, lung and eye cancers. This collaboration is expected to run for several years and the costs will be shared.
 
“Above and beyond the prospect of being able to bring additional therapeutic solutions to our patients in a short space of time, we welcome the opportunity of being able to assist the development of an early stage innovative company,” said Damien Salauze, the director of Curie-Cancer. “It is another example of how the Institut Curie’s know-how and the experimental models it has developed for fundamental research meet the needs of our industrial partners.”
 
About Curie-Cancer
Curie-Cancer is the body responsible for developing Institut Curie’s industry partnership activities. Set up in 2003, it oversees the institute’s existing industry partnerships as well as areas of high potential interest to industry partners. Institut Curie’s 1,200 researchers provide the high level of expertise in oncology required to collaborate with industry partners in creating and subsequently developing cancer therapies.
Curie-Cancer management has extensive industry experience and can call upon a vast pool of scientists involved in basic and clinical research. It currently has 91 ongoing industry collaborations (as of 2011). In 2011, Curie-Cancer was awarded the “Institut Carnot” label by the French government, which recognizes excellence and involvement in research partnerships.

About Institut Curie
Institut Curie is a private foundation founded in 1909 by Marie Curie, the first woman Nobel prize-winner and the first Nobel prize-double winner. It is the leading comprehensive cancer center (combining research and patient care) in Europe. Institut Curie’s research center and hospital employ some 3,200 scientists, physicians, nurses, technicians and administrative staff. The institute’s current objectives include increasing the proportion of research programs carried out in partnership with industry so that research results can lead to faster availability of products and services for the benefit of patients.
For more information, go to: http://www.curie.fr/en

About Harmonic Pharma
Harmonic Pharma was founded in 2009 and is primarily engaged in the molecular repositioning of active principles of therapeutic interest. It possesses a portfolio of some 20 molecules spread across several therapeutic fields, including oncology, neurodegenerative diseases, diabetic complications, infectious diseases and chronic pulmonary diseases. In each of these therapeutic areas, Harmonic Pharma collaborates with private or public partners that are experts in their field. The therapeutic products it offers to pharmaceutical and biotech companies have thus been validated by robust experimental data and patent protected.
For further information, go to: http://www.harmonicpharma.com  

Mark Tidmarsh
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
mark@ala.com

Follow us on Twitter:https://twitter.com/ALA_Group

Brighton Business Centre  95 Ditchling Road  Brighton BN1 4ST  ENGLAND ;
Tel,Fax:  +44 1273 675400
55 rue Boissonade  75014 Paris  FRANCE
Tel:  +33 1 56 54 07 00  ;Fax:  +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION   


  • <<
  • >>